Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Magnetic Resonance Imaging, Cine | 77 | 2023 | 964 | 11.080 |
Why?
|
Myocardial Perfusion Imaging | 27 | 2023 | 554 | 5.250 |
Why?
|
Gadolinium | 29 | 2023 | 952 | 4.860 |
Why?
|
Myocardial Ischemia | 43 | 2024 | 2148 | 4.840 |
Why?
|
Myocardium | 49 | 2022 | 4776 | 4.810 |
Why?
|
Cardiomyopathies | 38 | 2023 | 1912 | 4.610 |
Why?
|
Myocarditis | 19 | 2023 | 771 | 4.080 |
Why?
|
Coronary Artery Disease | 56 | 2024 | 6487 | 3.820 |
Why?
|
Ventricular Remodeling | 25 | 2022 | 1224 | 3.770 |
Why?
|
Contrast Media | 59 | 2023 | 5300 | 3.710 |
Why?
|
Magnetic Resonance Imaging | 116 | 2023 | 35421 | 3.520 |
Why?
|
Ventricular Function, Left | 48 | 2023 | 3670 | 3.290 |
Why?
|
Myocardial Infarction | 41 | 2024 | 11727 | 2.800 |
Why?
|
Predictive Value of Tests | 98 | 2023 | 15076 | 2.610 |
Why?
|
Cardiac Imaging Techniques | 14 | 2021 | 269 | 2.320 |
Why?
|
Gadolinium DTPA | 20 | 2019 | 836 | 2.300 |
Why?
|
Heart Ventricles | 28 | 2020 | 3821 | 2.280 |
Why?
|
Amyloidosis | 17 | 2022 | 795 | 2.200 |
Why?
|
Cardiomyopathy, Dilated | 7 | 2019 | 851 | 2.170 |
Why?
|
Stroke Volume | 41 | 2023 | 5007 | 2.050 |
Why?
|
Heart Diseases | 16 | 2023 | 2788 | 1.950 |
Why?
|
Cardiomyopathy, Hypertrophic | 19 | 2022 | 1265 | 1.900 |
Why?
|
Fatty Acids, Omega-3 | 5 | 2024 | 1344 | 1.830 |
Why?
|
Heart Atria | 13 | 2022 | 1357 | 1.790 |
Why?
|
Cicatrix | 8 | 2022 | 764 | 1.790 |
Why?
|
Fractional Flow Reserve, Myocardial | 10 | 2022 | 290 | 1.760 |
Why?
|
Coronary Circulation | 21 | 2020 | 1572 | 1.730 |
Why?
|
Atrial Function, Left | 4 | 2015 | 173 | 1.630 |
Why?
|
Death, Sudden, Cardiac | 14 | 2023 | 1541 | 1.510 |
Why?
|
Coronary Angiography | 31 | 2023 | 4577 | 1.460 |
Why?
|
Prognosis | 73 | 2023 | 29063 | 1.420 |
Why?
|
Heart Failure | 24 | 2023 | 10900 | 1.390 |
Why?
|
Magnetic Resonance Spectroscopy | 24 | 2023 | 3760 | 1.360 |
Why?
|
Exercise Test | 17 | 2020 | 2074 | 1.320 |
Why?
|
Chest Pain | 7 | 2022 | 1114 | 1.240 |
Why?
|
Coronary Vessel Anomalies | 2 | 2023 | 314 | 1.190 |
Why?
|
Electrocardiography | 29 | 2020 | 6442 | 1.150 |
Why?
|
Pulmonary Veins | 5 | 2014 | 761 | 1.090 |
Why?
|
Fibrosis | 17 | 2021 | 2029 | 1.070 |
Why?
|
Vasodilator Agents | 8 | 2019 | 977 | 1.040 |
Why?
|
Coronary Vessels | 13 | 2023 | 3107 | 1.030 |
Why?
|
Tachycardia, Ventricular | 6 | 2023 | 1273 | 1.020 |
Why?
|
Atrial Fibrillation | 11 | 2021 | 5034 | 1.010 |
Why?
|
Humans | 298 | 2024 | 744343 | 0.980 |
Why?
|
Image Interpretation, Computer-Assisted | 10 | 2019 | 3327 | 0.910 |
Why?
|
Risk Assessment | 38 | 2024 | 23338 | 0.890 |
Why?
|
Image Enhancement | 8 | 2021 | 2921 | 0.890 |
Why?
|
Catheter Ablation | 8 | 2021 | 2758 | 0.860 |
Why?
|
Coronary Sinus | 3 | 2018 | 87 | 0.820 |
Why?
|
Biofuels | 1 | 2021 | 41 | 0.810 |
Why?
|
Hypertrophy, Left Ventricular | 10 | 2021 | 859 | 0.810 |
Why?
|
Echocardiography | 24 | 2021 | 5102 | 0.810 |
Why?
|
Magnetic Resonance Angiography | 11 | 2020 | 1442 | 0.790 |
Why?
|
Positron-Emission Tomography | 21 | 2022 | 6234 | 0.780 |
Why?
|
Ventricular Dysfunction, Left | 9 | 2015 | 2073 | 0.770 |
Why?
|
Ventricular Function | 4 | 2016 | 416 | 0.770 |
Why?
|
Arrhythmias, Cardiac | 8 | 2023 | 2268 | 0.770 |
Why?
|
Middle Aged | 120 | 2024 | 213383 | 0.740 |
Why?
|
Male | 151 | 2024 | 350118 | 0.720 |
Why?
|
Female | 154 | 2024 | 380194 | 0.720 |
Why?
|
Coronary Disease | 11 | 2023 | 6077 | 0.700 |
Why?
|
Extracellular Matrix | 5 | 2014 | 1741 | 0.700 |
Why?
|
Tissue Survival | 4 | 2020 | 118 | 0.690 |
Why?
|
Fatty Acid Desaturases | 1 | 2019 | 102 | 0.690 |
Why?
|
Anthracyclines | 3 | 2023 | 288 | 0.660 |
Why?
|
Aged | 94 | 2023 | 163280 | 0.640 |
Why?
|
Myocardial Contraction | 7 | 2019 | 1585 | 0.610 |
Why?
|
Amyloid Neuropathies, Familial | 2 | 2023 | 138 | 0.580 |
Why?
|
Cardiology | 8 | 2023 | 1668 | 0.580 |
Why?
|
Heart Neoplasms | 5 | 2019 | 374 | 0.570 |
Why?
|
American Heart Association | 8 | 2023 | 1056 | 0.560 |
Why?
|
Risk Factors | 40 | 2023 | 72290 | 0.560 |
Why?
|
Climate Change | 1 | 2021 | 418 | 0.550 |
Why?
|
Tomography, X-Ray Computed | 23 | 2023 | 20129 | 0.550 |
Why?
|
Sarcomeres | 3 | 2014 | 374 | 0.550 |
Why?
|
Esters | 1 | 2017 | 210 | 0.540 |
Why?
|
Myocardial Revascularization | 8 | 2020 | 841 | 0.540 |
Why?
|
Acute Coronary Syndrome | 4 | 2024 | 2337 | 0.530 |
Why?
|
Perfusion | 5 | 2023 | 1360 | 0.530 |
Why?
|
Pericardium | 5 | 2017 | 667 | 0.530 |
Why?
|
Prealbumin | 3 | 2023 | 210 | 0.520 |
Why?
|
Sarcoidosis | 6 | 2019 | 506 | 0.510 |
Why?
|
Artificial Intelligence | 5 | 2023 | 2214 | 0.500 |
Why?
|
Coronary Stenosis | 4 | 2017 | 834 | 0.480 |
Why?
|
Microcirculation | 4 | 2014 | 1286 | 0.470 |
Why?
|
Adiponectin | 1 | 2019 | 1100 | 0.460 |
Why?
|
Dobutamine | 2 | 2011 | 123 | 0.460 |
Why?
|
Severity of Illness Index | 21 | 2020 | 15540 | 0.450 |
Why?
|
Amyloid | 2 | 2018 | 795 | 0.440 |
Why?
|
Cardiac Volume | 1 | 2013 | 210 | 0.440 |
Why?
|
Immunoglobulin Light Chains | 1 | 2014 | 277 | 0.440 |
Why?
|
Diabetic Angiopathies | 3 | 2017 | 818 | 0.430 |
Why?
|
Spironolactone | 4 | 2023 | 382 | 0.430 |
Why?
|
Echocardiography, Doppler | 4 | 2020 | 935 | 0.430 |
Why?
|
Prospective Studies | 35 | 2024 | 53288 | 0.420 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2020 | 2208 | 0.420 |
Why?
|
Radionuclide Imaging | 3 | 2021 | 2031 | 0.420 |
Why?
|
Aortic Valve Insufficiency | 1 | 2016 | 579 | 0.410 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2013 | 1873 | 0.410 |
Why?
|
Cardiomegaly | 2 | 2014 | 620 | 0.410 |
Why?
|
Defibrillators, Implantable | 5 | 2021 | 1440 | 0.410 |
Why?
|
Iron Overload | 5 | 2012 | 242 | 0.410 |
Why?
|
Follow-Up Studies | 26 | 2023 | 39050 | 0.400 |
Why?
|
Leptin | 1 | 2019 | 1599 | 0.400 |
Why?
|
Molecular Imaging | 3 | 2019 | 828 | 0.400 |
Why?
|
Reproducibility of Results | 30 | 2021 | 19905 | 0.400 |
Why?
|
Rubidium Radioisotopes | 6 | 2013 | 85 | 0.390 |
Why?
|
Cardiotonic Agents | 2 | 2011 | 535 | 0.390 |
Why?
|
Brain Abscess | 1 | 2011 | 118 | 0.380 |
Why?
|
Technology Assessment, Biomedical | 1 | 2013 | 306 | 0.380 |
Why?
|
Vena Cava, Superior | 1 | 2011 | 193 | 0.380 |
Why?
|
Heart Septum | 2 | 2009 | 313 | 0.380 |
Why?
|
Adult | 59 | 2024 | 214055 | 0.360 |
Why?
|
Parvovirus B19, Human | 1 | 2010 | 38 | 0.360 |
Why?
|
Heart Transplantation | 3 | 2019 | 3110 | 0.360 |
Why?
|
Biopsy | 9 | 2021 | 6756 | 0.360 |
Why?
|
Cardiovascular System | 3 | 2022 | 832 | 0.350 |
Why?
|
Cardiovascular Diseases | 15 | 2022 | 15165 | 0.350 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2010 | 93 | 0.350 |
Why?
|
Edema | 1 | 2014 | 789 | 0.350 |
Why?
|
Diagnostic Techniques, Cardiovascular | 2 | 2021 | 153 | 0.340 |
Why?
|
Mitochondria, Heart | 1 | 2011 | 247 | 0.340 |
Why?
|
Medical Oncology | 1 | 2021 | 2265 | 0.340 |
Why?
|
Pericarditis, Constrictive | 1 | 2009 | 42 | 0.340 |
Why?
|
Perfusion Imaging | 2 | 2021 | 195 | 0.340 |
Why?
|
Registries | 11 | 2023 | 8089 | 0.340 |
Why?
|
Radiographic Image Enhancement | 2 | 2013 | 885 | 0.340 |
Why?
|
Ventricular Dysfunction, Right | 2 | 2022 | 581 | 0.340 |
Why?
|
Fluorodeoxyglucose F18 | 7 | 2024 | 2016 | 0.330 |
Why?
|
Cardiomyopathy, Restrictive | 1 | 2009 | 60 | 0.330 |
Why?
|
Diagnostic Imaging | 6 | 2017 | 3507 | 0.330 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2013 | 546 | 0.330 |
Why?
|
Aortic Valve Stenosis | 3 | 2017 | 1965 | 0.320 |
Why?
|
Inflammation | 5 | 2023 | 10638 | 0.320 |
Why?
|
Proportional Hazards Models | 12 | 2014 | 12354 | 0.320 |
Why?
|
Treatment Outcome | 27 | 2024 | 63114 | 0.320 |
Why?
|
Arrhythmogenic Right Ventricular Dysplasia | 2 | 2008 | 161 | 0.310 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3133 | 0.310 |
Why?
|
Myocardial Reperfusion | 2 | 2008 | 351 | 0.310 |
Why?
|
Insulin Resistance | 2 | 2019 | 3864 | 0.310 |
Why?
|
Kaplan-Meier Estimate | 9 | 2020 | 6538 | 0.310 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3240 | 0.310 |
Why?
|
Retrospective Studies | 27 | 2023 | 77449 | 0.310 |
Why?
|
Angina Pectoris | 5 | 2023 | 977 | 0.310 |
Why?
|
Eicosapentaenoic Acid | 2 | 2024 | 582 | 0.300 |
Why?
|
Observer Variation | 11 | 2019 | 2593 | 0.300 |
Why?
|
Streptococcal Infections | 1 | 2011 | 638 | 0.300 |
Why?
|
Sensitivity and Specificity | 16 | 2019 | 14722 | 0.290 |
Why?
|
Hypertension | 8 | 2021 | 8480 | 0.290 |
Why?
|
Organometallic Compounds | 3 | 2019 | 665 | 0.290 |
Why?
|
Time Factors | 23 | 2022 | 40075 | 0.290 |
Why?
|
Coronary Thrombosis | 1 | 2010 | 495 | 0.280 |
Why?
|
Algorithms | 7 | 2015 | 13881 | 0.280 |
Why?
|
Meglumine | 2 | 2019 | 149 | 0.280 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 2006 | 40 | 0.280 |
Why?
|
Adipose Tissue | 3 | 2017 | 3279 | 0.280 |
Why?
|
Pilot Projects | 11 | 2024 | 8324 | 0.280 |
Why?
|
Pandemics | 3 | 2020 | 8388 | 0.270 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2012 | 531 | 0.270 |
Why?
|
Renal Dialysis | 3 | 2021 | 1786 | 0.260 |
Why?
|
Diabetes Mellitus | 2 | 2016 | 5751 | 0.260 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2009 | 845 | 0.260 |
Why?
|
Seeds | 2 | 2003 | 105 | 0.260 |
Why?
|
Cardiac-Gated Imaging Techniques | 3 | 2015 | 143 | 0.260 |
Why?
|
Radiopharmaceuticals | 8 | 2021 | 2645 | 0.250 |
Why?
|
Myocardial Reperfusion Injury | 2 | 2023 | 476 | 0.250 |
Why?
|
Atrial Flutter | 1 | 2007 | 263 | 0.250 |
Why?
|
Fibroma | 1 | 2006 | 212 | 0.250 |
Why?
|
Cerebral Infarction | 1 | 2010 | 1011 | 0.250 |
Why?
|
Heart | 6 | 2022 | 4467 | 0.250 |
Why?
|
Neoplasms | 7 | 2021 | 21683 | 0.250 |
Why?
|
Consensus | 11 | 2021 | 2959 | 0.240 |
Why?
|
Double-Blind Method | 7 | 2023 | 12026 | 0.240 |
Why?
|
Obesity | 6 | 2021 | 12745 | 0.240 |
Why?
|
Disease-Free Survival | 7 | 2018 | 6895 | 0.240 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 2 | 2003 | 286 | 0.240 |
Why?
|
Fish Oils | 2 | 2018 | 470 | 0.230 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2013 | 1813 | 0.230 |
Why?
|
Disease Progression | 9 | 2019 | 13284 | 0.230 |
Why?
|
Systole | 3 | 2017 | 958 | 0.230 |
Why?
|
Aortic Diseases | 1 | 2009 | 742 | 0.220 |
Why?
|
Purines | 2 | 2019 | 594 | 0.220 |
Why?
|
Societies, Medical | 6 | 2020 | 3743 | 0.220 |
Why?
|
Plant Proteins | 2 | 2003 | 364 | 0.220 |
Why?
|
Myocardial Bridging | 1 | 2022 | 11 | 0.220 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 4 | 2022 | 314 | 0.220 |
Why?
|
Cosmetics | 1 | 2024 | 97 | 0.220 |
Why?
|
Organ Size | 3 | 2016 | 2252 | 0.220 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 7 | 2020 | 1107 | 0.210 |
Why?
|
Metals, Heavy | 1 | 2024 | 139 | 0.210 |
Why?
|
Ethylene Glycols | 2 | 2020 | 156 | 0.210 |
Why?
|
Coronary Artery Bypass | 3 | 2022 | 2289 | 0.210 |
Why?
|
Diabetes Complications | 2 | 2012 | 1359 | 0.210 |
Why?
|
Ventricular Function, Right | 4 | 2023 | 591 | 0.210 |
Why?
|
Hematoma | 1 | 2007 | 758 | 0.210 |
Why?
|
Serum Amyloid P-Component | 1 | 2022 | 47 | 0.210 |
Why?
|
Arteritis | 1 | 2024 | 159 | 0.200 |
Why?
|
Tongue Neoplasms | 1 | 2003 | 180 | 0.200 |
Why?
|
Genes, Regulator | 1 | 2003 | 378 | 0.200 |
Why?
|
Arabidopsis | 2 | 2003 | 459 | 0.200 |
Why?
|
Diagnosis, Differential | 9 | 2019 | 12959 | 0.200 |
Why?
|
Carboxylic Acids | 1 | 2022 | 97 | 0.200 |
Why?
|
Arterial Occlusive Diseases | 1 | 2006 | 793 | 0.200 |
Why?
|
Endomyocardial Fibrosis | 2 | 2012 | 41 | 0.200 |
Why?
|
Entropy | 1 | 2022 | 209 | 0.200 |
Why?
|
Mitral Valve Annuloplasty | 1 | 2022 | 143 | 0.190 |
Why?
|
United States | 27 | 2023 | 69872 | 0.190 |
Why?
|
Atherosclerosis | 4 | 2024 | 3445 | 0.190 |
Why?
|
Recurrence | 5 | 2014 | 8340 | 0.180 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2022 | 272 | 0.180 |
Why?
|
Terminology as Topic | 2 | 2019 | 1547 | 0.180 |
Why?
|
Blood Glucose | 4 | 2014 | 6256 | 0.180 |
Why?
|
Pyrrolidines | 1 | 2022 | 342 | 0.180 |
Why?
|
Benzylamines | 1 | 2020 | 223 | 0.180 |
Why?
|
Cost-Benefit Analysis | 6 | 2022 | 5391 | 0.180 |
Why?
|
Proinsulin | 1 | 2019 | 133 | 0.180 |
Why?
|
Uracil | 1 | 2020 | 165 | 0.170 |
Why?
|
Pericardial Effusion | 1 | 2021 | 247 | 0.170 |
Why?
|
Multivariate Analysis | 7 | 2014 | 12245 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 692 | 0.170 |
Why?
|
Canada | 3 | 2021 | 2065 | 0.170 |
Why?
|
Freedom | 1 | 2019 | 69 | 0.170 |
Why?
|
Receptors, Mineralocorticoid | 2 | 2024 | 164 | 0.170 |
Why?
|
Mitral Valve Insufficiency | 3 | 2022 | 1422 | 0.160 |
Why?
|
Tomography, Optical Coherence | 2 | 2021 | 2657 | 0.160 |
Why?
|
Angiography | 2 | 2014 | 1639 | 0.160 |
Why?
|
Linoleic Acid | 1 | 2019 | 157 | 0.160 |
Why?
|
Aorta, Thoracic | 2 | 2015 | 1082 | 0.160 |
Why?
|
Heart Rupture | 1 | 1998 | 23 | 0.160 |
Why?
|
Aniline Compounds | 2 | 2020 | 986 | 0.160 |
Why?
|
Arachidonic Acid | 1 | 2019 | 434 | 0.160 |
Why?
|
C-Peptide | 1 | 2019 | 419 | 0.160 |
Why?
|
Equipment Safety | 1 | 2018 | 264 | 0.150 |
Why?
|
Myelodysplastic Syndromes | 3 | 2012 | 1352 | 0.150 |
Why?
|
Myocytes, Cardiac | 3 | 2018 | 1637 | 0.150 |
Why?
|
Chronic Disease | 7 | 2024 | 9146 | 0.150 |
Why?
|
Hemorrhage | 1 | 2009 | 3461 | 0.150 |
Why?
|
Fluorine Radioisotopes | 1 | 2020 | 442 | 0.150 |
Why?
|
Mutation | 7 | 2016 | 29786 | 0.150 |
Why?
|
Linear Models | 5 | 2015 | 5952 | 0.140 |
Why?
|
Young Adult | 16 | 2019 | 56430 | 0.140 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 850 | 0.140 |
Why?
|
Heart Defects, Congenital | 4 | 2015 | 4584 | 0.140 |
Why?
|
Cohort Studies | 8 | 2023 | 40561 | 0.140 |
Why?
|
Vasodilation | 2 | 2019 | 944 | 0.140 |
Why?
|
ROC Curve | 4 | 2015 | 3527 | 0.140 |
Why?
|
Evidence-Based Medicine | 5 | 2021 | 3610 | 0.140 |
Why?
|
Ferrosoferric Oxide | 1 | 2017 | 360 | 0.140 |
Why?
|
RNA, Small Nucleolar | 1 | 2016 | 31 | 0.140 |
Why?
|
Internationality | 1 | 2022 | 1003 | 0.140 |
Why?
|
Infection Control | 2 | 2020 | 966 | 0.140 |
Why?
|
Transplantation Conditioning | 3 | 2012 | 1598 | 0.140 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2017 | 281 | 0.140 |
Why?
|
Pulmonary Artery | 2 | 2015 | 1912 | 0.140 |
Why?
|
Pyrazoles | 2 | 2019 | 1972 | 0.140 |
Why?
|
Patient Selection | 6 | 2019 | 4215 | 0.140 |
Why?
|
Radiography | 5 | 2011 | 7023 | 0.140 |
Why?
|
Angina, Unstable | 3 | 2020 | 926 | 0.140 |
Why?
|
Hemodynamics | 3 | 2016 | 4199 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2018 | 11725 | 0.130 |
Why?
|
Aged, 80 and over | 10 | 2022 | 57776 | 0.130 |
Why?
|
Societies, Scientific | 1 | 2017 | 220 | 0.130 |
Why?
|
Aortic Valve | 2 | 2016 | 1922 | 0.130 |
Why?
|
Aorta | 1 | 2023 | 2061 | 0.130 |
Why?
|
Chi-Square Distribution | 4 | 2016 | 3508 | 0.130 |
Why?
|
Electric Countershock | 1 | 2018 | 534 | 0.130 |
Why?
|
Survival Rate | 4 | 2014 | 12788 | 0.130 |
Why?
|
Echocardiography, Transesophageal | 4 | 2020 | 1133 | 0.130 |
Why?
|
Body Water | 2 | 2013 | 343 | 0.130 |
Why?
|
Adiposity | 3 | 2017 | 1807 | 0.120 |
Why?
|
Pentalogy of Cantrell | 1 | 2014 | 1 | 0.120 |
Why?
|
Extracellular Space | 2 | 2013 | 594 | 0.120 |
Why?
|
Ventricular Premature Complexes | 1 | 2015 | 111 | 0.120 |
Why?
|
Myeloablative Agonists | 2 | 2012 | 218 | 0.120 |
Why?
|
Plethysmography, Impedance | 1 | 2014 | 43 | 0.120 |
Why?
|
Decision Support Techniques | 2 | 2016 | 1956 | 0.120 |
Why?
|
Diltiazem | 1 | 2014 | 133 | 0.120 |
Why?
|
Recovery of Function | 3 | 2014 | 2925 | 0.120 |
Why?
|
Safety Management | 1 | 2020 | 783 | 0.120 |
Why?
|
Lymphoma | 1 | 2023 | 1877 | 0.120 |
Why?
|
Boston | 3 | 2011 | 9313 | 0.120 |
Why?
|
Calcinosis | 3 | 2009 | 1499 | 0.120 |
Why?
|
Scimitar Syndrome | 1 | 2014 | 31 | 0.120 |
Why?
|
Heart Rate | 2 | 2015 | 4091 | 0.120 |
Why?
|
Transcription Factors | 3 | 2003 | 12208 | 0.110 |
Why?
|
Echocardiography, Stress | 1 | 2014 | 131 | 0.110 |
Why?
|
Stem Cell Transplantation | 2 | 2012 | 1620 | 0.110 |
Why?
|
Nausea | 1 | 2016 | 673 | 0.110 |
Why?
|
Wireless Technology | 1 | 2014 | 100 | 0.110 |
Why?
|
Respiratory Rate | 1 | 2014 | 162 | 0.110 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2020 | 1320 | 0.110 |
Why?
|
Docosahexaenoic Acids | 1 | 2019 | 875 | 0.110 |
Why?
|
Diastole | 2 | 2014 | 791 | 0.110 |
Why?
|
Image Processing, Computer-Assisted | 7 | 2021 | 8949 | 0.110 |
Why?
|
Incidence | 5 | 2020 | 20947 | 0.110 |
Why?
|
Streptococcus intermedius | 1 | 2011 | 4 | 0.110 |
Why?
|
Chelation Therapy | 1 | 2012 | 67 | 0.110 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2014 | 182 | 0.100 |
Why?
|
Hydrochlorothiazide | 2 | 2014 | 98 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.100 |
Why?
|
Feasibility Studies | 4 | 2014 | 5078 | 0.100 |
Why?
|
Lysosomal Storage Diseases | 1 | 2012 | 79 | 0.100 |
Why?
|
Cell Cycle Proteins | 1 | 2003 | 3462 | 0.100 |
Why?
|
Athletes | 1 | 2019 | 1093 | 0.100 |
Why?
|
Forecasting | 2 | 2020 | 2951 | 0.100 |
Why?
|
Troponin T | 1 | 2016 | 754 | 0.100 |
Why?
|
Abscess | 1 | 2015 | 607 | 0.100 |
Why?
|
Calcium Channel Blockers | 1 | 2014 | 690 | 0.100 |
Why?
|
Iron Chelating Agents | 1 | 2012 | 139 | 0.100 |
Why?
|
Blood Pressure | 5 | 2021 | 8554 | 0.100 |
Why?
|
Radiosurgery | 1 | 2021 | 1329 | 0.100 |
Why?
|
Peptide Fragments | 2 | 2016 | 5097 | 0.100 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1439 | 0.100 |
Why?
|
Primary Prevention | 1 | 2018 | 1167 | 0.100 |
Why?
|
Natriuretic Peptide, Brain | 2 | 2016 | 1573 | 0.090 |
Why?
|
Endocarditis, Bacterial | 1 | 2015 | 455 | 0.090 |
Why?
|
Magnetics | 1 | 2014 | 606 | 0.090 |
Why?
|
Nephrogenic Fibrosing Dermopathy | 1 | 2010 | 42 | 0.090 |
Why?
|
Blood Circulation | 1 | 2011 | 251 | 0.090 |
Why?
|
Capillary Permeability | 1 | 2014 | 798 | 0.090 |
Why?
|
Enalapril | 3 | 2018 | 327 | 0.090 |
Why?
|
Disease Models, Animal | 8 | 2016 | 18029 | 0.090 |
Why?
|
Advisory Committees | 1 | 2015 | 775 | 0.090 |
Why?
|
Metoprolol | 1 | 2011 | 93 | 0.090 |
Why?
|
Bone Marrow Transplantation | 2 | 2010 | 2765 | 0.090 |
Why?
|
Heterozygote | 2 | 2014 | 2804 | 0.090 |
Why?
|
Heart Aneurysm | 1 | 2010 | 120 | 0.090 |
Why?
|
Syncope | 2 | 2010 | 429 | 0.090 |
Why?
|
Doxorubicin | 1 | 2016 | 2234 | 0.090 |
Why?
|
Microvessels | 1 | 2014 | 544 | 0.090 |
Why?
|
Acute Disease | 4 | 2012 | 7149 | 0.090 |
Why?
|
Procollagen | 1 | 2010 | 185 | 0.090 |
Why?
|
Erythrocytes | 1 | 2019 | 2455 | 0.090 |
Why?
|
Carotid Arteries | 1 | 2014 | 952 | 0.090 |
Why?
|
Heart Septal Defects, Ventricular | 1 | 2012 | 488 | 0.090 |
Why?
|
Heterocyclic Compounds | 1 | 2010 | 249 | 0.090 |
Why?
|
Odds Ratio | 4 | 2016 | 9849 | 0.090 |
Why?
|
Intra-Abdominal Fat | 1 | 2014 | 591 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2014 | 1518 | 0.090 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2009 | 46 | 0.080 |
Why?
|
Telemetry | 1 | 2010 | 205 | 0.080 |
Why?
|
Diuretics | 2 | 2014 | 592 | 0.080 |
Why?
|
Models, Cardiovascular | 3 | 2015 | 996 | 0.080 |
Why?
|
Chagas Cardiomyopathy | 1 | 2009 | 72 | 0.080 |
Why?
|
Arabidopsis Proteins | 2 | 2003 | 262 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2014 | 3047 | 0.080 |
Why?
|
Fabry Disease | 1 | 2009 | 90 | 0.080 |
Why?
|
European Union | 1 | 2009 | 158 | 0.080 |
Why?
|
Prevalence | 4 | 2016 | 15226 | 0.080 |
Why?
|
Tomography, Emission-Computed | 1 | 2012 | 1144 | 0.080 |
Why?
|
Foreign-Body Migration | 1 | 2010 | 222 | 0.080 |
Why?
|
Ischemia | 3 | 2022 | 1907 | 0.080 |
Why?
|
Aldosterone | 1 | 2013 | 877 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2017 | 2046 | 0.080 |
Why?
|
Mitral Valve | 2 | 2022 | 1491 | 0.080 |
Why?
|
Logistic Models | 4 | 2014 | 13408 | 0.080 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2016 | 1536 | 0.080 |
Why?
|
Delphi Technique | 2 | 2021 | 778 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2003 | 4034 | 0.080 |
Why?
|
Vena Cava Filters | 1 | 2010 | 252 | 0.080 |
Why?
|
Heart Valve Prosthesis | 1 | 2016 | 1488 | 0.080 |
Why?
|
Cardiac Surgical Procedures | 3 | 2011 | 3537 | 0.080 |
Why?
|
Age Factors | 4 | 2019 | 18370 | 0.080 |
Why?
|
Paraganglioma | 1 | 2009 | 143 | 0.070 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2015 | 1184 | 0.070 |
Why?
|
HIV Infections | 2 | 2024 | 16718 | 0.070 |
Why?
|
Capillaries | 1 | 2010 | 773 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2018 | 2899 | 0.070 |
Why?
|
Pericardiocentesis | 1 | 2007 | 74 | 0.070 |
Why?
|
Radioisotopes | 1 | 2008 | 499 | 0.070 |
Why?
|
Embolism | 1 | 2010 | 408 | 0.070 |
Why?
|
Collagen | 2 | 2013 | 2689 | 0.070 |
Why?
|
Massachusetts | 3 | 2014 | 8663 | 0.070 |
Why?
|
Swine | 3 | 2014 | 5917 | 0.070 |
Why?
|
Carotid Stenosis | 1 | 2014 | 854 | 0.070 |
Why?
|
Hypotension | 2 | 2017 | 884 | 0.070 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7279 | 0.070 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3505 | 0.070 |
Why?
|
Equipment Design | 3 | 2014 | 3582 | 0.070 |
Why?
|
Adolescent | 13 | 2018 | 85781 | 0.070 |
Why?
|
DNA-Binding Proteins | 2 | 2003 | 9648 | 0.070 |
Why?
|
Sex Factors | 3 | 2020 | 10397 | 0.070 |
Why?
|
Nuclear Medicine | 2 | 2019 | 233 | 0.070 |
Why?
|
Prostheses and Implants | 1 | 2014 | 1387 | 0.070 |
Why?
|
Case-Control Studies | 5 | 2016 | 21746 | 0.070 |
Why?
|
Life Tables | 1 | 2006 | 370 | 0.070 |
Why?
|
Cardiac Tamponade | 1 | 2007 | 173 | 0.070 |
Why?
|
Aging | 2 | 2016 | 8664 | 0.070 |
Why?
|
RNA, Plant | 2 | 2003 | 29 | 0.070 |
Why?
|
Stress, Physiological | 1 | 2013 | 1403 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2014 | 1018 | 0.070 |
Why?
|
Sleep Apnea Syndromes | 1 | 2014 | 944 | 0.070 |
Why?
|
Asymptomatic Diseases | 2 | 2020 | 551 | 0.070 |
Why?
|
Iron | 2 | 2012 | 1774 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2012 | 3523 | 0.070 |
Why?
|
Prosthesis Failure | 1 | 2010 | 1206 | 0.060 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2010 | 591 | 0.060 |
Why?
|
Frontal Lobe | 1 | 2011 | 1406 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9274 | 0.060 |
Why?
|
Sheep | 3 | 2014 | 1437 | 0.060 |
Why?
|
Blood Flow Velocity | 2 | 2018 | 1423 | 0.060 |
Why?
|
Gene Expression Regulation, Plant | 2 | 2003 | 201 | 0.060 |
Why?
|
Survivors | 1 | 2015 | 2291 | 0.060 |
Why?
|
Body Mass Index | 4 | 2014 | 12720 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 7913 | 0.060 |
Why?
|
Autoimmunity | 1 | 2012 | 1349 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2013 | 4186 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 4 | 2015 | 4042 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2013 | 6365 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2635 | 0.060 |
Why?
|
Animals | 17 | 2020 | 168757 | 0.060 |
Why?
|
Phenotype | 4 | 2016 | 16365 | 0.060 |
Why?
|
Creatine Kinase | 1 | 2006 | 694 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1511 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2016 | 13989 | 0.060 |
Why?
|
NG-Nitroarginine Methyl Ester | 2 | 2014 | 255 | 0.060 |
Why?
|
MicroRNAs | 2 | 2018 | 3752 | 0.060 |
Why?
|
Hearing Loss | 1 | 2011 | 765 | 0.060 |
Why?
|
Emergency Service, Hospital | 1 | 2003 | 7659 | 0.060 |
Why?
|
Calcium | 2 | 2009 | 5756 | 0.060 |
Why?
|
E2F1 Transcription Factor | 1 | 2003 | 190 | 0.060 |
Why?
|
Lipomatosis | 1 | 2004 | 112 | 0.060 |
Why?
|
E2F Transcription Factors | 1 | 2003 | 277 | 0.060 |
Why?
|
Hypertension, Pulmonary | 1 | 2014 | 1537 | 0.060 |
Why?
|
Models, Biological | 1 | 2019 | 9583 | 0.050 |
Why?
|
Weight Loss | 1 | 2014 | 2622 | 0.050 |
Why?
|
Ultrasonography | 2 | 2007 | 5985 | 0.050 |
Why?
|
Genome, Human | 1 | 2016 | 4420 | 0.050 |
Why?
|
Artifacts | 2 | 2015 | 1904 | 0.050 |
Why?
|
Fever | 1 | 2010 | 1616 | 0.050 |
Why?
|
Exercise | 2 | 2016 | 5615 | 0.050 |
Why?
|
Research Design | 2 | 2017 | 5987 | 0.050 |
Why?
|
Dyspnea | 1 | 2010 | 1303 | 0.050 |
Why?
|
Health Care Costs | 1 | 2016 | 3209 | 0.050 |
Why?
|
Electrodes | 2 | 2015 | 619 | 0.050 |
Why?
|
Lip | 1 | 2024 | 195 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2017 | 4371 | 0.050 |
Why?
|
Genetic Testing | 1 | 2015 | 3444 | 0.050 |
Why?
|
Disease Management | 1 | 2012 | 2459 | 0.050 |
Why?
|
Bayes Theorem | 2 | 2020 | 2309 | 0.050 |
Why?
|
Pattern Recognition, Automated | 1 | 2008 | 1005 | 0.050 |
Why?
|
Drug Therapy, Combination | 4 | 2022 | 6489 | 0.050 |
Why?
|
Carcinogens | 1 | 2024 | 466 | 0.050 |
Why?
|
Cyclin D1 | 1 | 2003 | 463 | 0.050 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 1519 | 0.050 |
Why?
|
Radiation Dosage | 1 | 2010 | 1928 | 0.050 |
Why?
|
Equipment Failure Analysis | 2 | 2014 | 868 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2003 | 644 | 0.050 |
Why?
|
Regression Analysis | 1 | 2011 | 6459 | 0.050 |
Why?
|
Adenosine | 1 | 2006 | 825 | 0.050 |
Why?
|
Analgesics | 1 | 1988 | 1040 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2282 | 0.050 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2003 | 2839 | 0.050 |
Why?
|
Risk | 2 | 2009 | 9687 | 0.050 |
Why?
|
Ligation | 2 | 2012 | 453 | 0.050 |
Why?
|
Catheterization | 1 | 2006 | 1470 | 0.050 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 705 | 0.050 |
Why?
|
Survival Analysis | 3 | 2010 | 10252 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15519 | 0.040 |
Why?
|
Diabetic Nephropathies | 1 | 2007 | 984 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 4 | 2016 | 17446 | 0.040 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2012 | 3336 | 0.040 |
Why?
|
Retinoblastoma Protein | 1 | 2003 | 704 | 0.040 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2021 | 236 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2003 | 1005 | 0.040 |
Why?
|
Multigene Family | 1 | 2003 | 1102 | 0.040 |
Why?
|
Costs and Cost Analysis | 2 | 2022 | 1681 | 0.040 |
Why?
|
Thrombosis | 2 | 2017 | 2968 | 0.040 |
Why?
|
Respiration | 1 | 2006 | 1653 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2018 | 25043 | 0.040 |
Why?
|
Troponin | 1 | 2003 | 524 | 0.040 |
Why?
|
Europe | 2 | 2016 | 3339 | 0.040 |
Why?
|
In Situ Hybridization | 1 | 2003 | 1950 | 0.040 |
Why?
|
Ferritins | 2 | 2012 | 590 | 0.040 |
Why?
|
Taxoids | 1 | 2002 | 666 | 0.040 |
Why?
|
Goals | 1 | 2024 | 706 | 0.040 |
Why?
|
Lead | 1 | 2024 | 852 | 0.040 |
Why?
|
Quality of Life | 5 | 2020 | 12804 | 0.040 |
Why?
|
Genes, Plant | 1 | 1998 | 124 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2022 | 1107 | 0.040 |
Why?
|
Palliative Care | 3 | 2002 | 3493 | 0.040 |
Why?
|
Tremor | 3 | 1988 | 175 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2002 | 624 | 0.040 |
Why?
|
China | 1 | 2024 | 2248 | 0.040 |
Why?
|
Cell Survival | 1 | 2008 | 5882 | 0.040 |
Why?
|
RNA, Small Untranslated | 1 | 2018 | 76 | 0.040 |
Why?
|
Hypertrophy | 2 | 2013 | 569 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 2015 | 1534 | 0.040 |
Why?
|
Diagnostic Tests, Routine | 1 | 2023 | 783 | 0.040 |
Why?
|
Environmental Monitoring | 1 | 2024 | 1414 | 0.040 |
Why?
|
Hospitalization | 3 | 2017 | 10262 | 0.040 |
Why?
|
Edema, Cardiac | 1 | 2016 | 18 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2012 | 5442 | 0.040 |
Why?
|
Terminal Care | 1 | 1988 | 1694 | 0.040 |
Why?
|
Comorbidity | 2 | 2012 | 10388 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2020 | 2327 | 0.030 |
Why?
|
Thalamic Nuclei | 2 | 1988 | 114 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 847 | 0.030 |
Why?
|
HIV | 1 | 2023 | 1604 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1643 | 0.030 |
Why?
|
Urinary Calculi | 1 | 1996 | 91 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11124 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 16689 | 0.030 |
Why?
|
Phylogeny | 1 | 2003 | 2803 | 0.030 |
Why?
|
X-Ray Diffraction | 1 | 1996 | 420 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1184 | 0.030 |
Why?
|
Inflammation Mediators | 2 | 2014 | 1889 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2003 | 13815 | 0.030 |
Why?
|
Digoxin | 1 | 1995 | 250 | 0.030 |
Why?
|
Organizational Objectives | 1 | 2017 | 438 | 0.030 |
Why?
|
Immunoglobulin Variable Region | 1 | 1995 | 421 | 0.030 |
Why?
|
Paclitaxel | 1 | 2002 | 1708 | 0.030 |
Why?
|
Body Weight | 2 | 2017 | 4669 | 0.030 |
Why?
|
Simvastatin | 1 | 2017 | 360 | 0.030 |
Why?
|
Glycolysis | 1 | 2018 | 827 | 0.030 |
Why?
|
Iohexol | 1 | 2015 | 196 | 0.030 |
Why?
|
Emergency Medical Services | 1 | 2006 | 1917 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2879 | 0.030 |
Why?
|
Anastomosis, Surgical | 1 | 2017 | 987 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2022 | 2513 | 0.030 |
Why?
|
Mice | 7 | 2020 | 81183 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2018 | 783 | 0.030 |
Why?
|
Scattering, Radiation | 1 | 1996 | 498 | 0.030 |
Why?
|
Temperature | 1 | 2020 | 2206 | 0.030 |
Why?
|
Child, Preschool | 5 | 2015 | 41006 | 0.030 |
Why?
|
Molecular Sequence Data | 3 | 2003 | 18111 | 0.030 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 1995 | 482 | 0.030 |
Why?
|
Occupational Health | 1 | 2020 | 809 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2023 | 1790 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2016 | 528 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2024 | 2585 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7181 | 0.030 |
Why?
|
Aortography | 1 | 2015 | 437 | 0.030 |
Why?
|
Veins | 1 | 2017 | 770 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20822 | 0.030 |
Why?
|
Transplantation, Homologous | 2 | 2012 | 4776 | 0.030 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2014 | 194 | 0.030 |
Why?
|
Sheep, Domestic | 1 | 2012 | 49 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2021 | 2480 | 0.030 |
Why?
|
Infusions, Subcutaneous | 1 | 2012 | 42 | 0.030 |
Why?
|
Arteries | 1 | 2017 | 1119 | 0.030 |
Why?
|
Bacteriophages | 1 | 1995 | 356 | 0.030 |
Why?
|
Thalamus | 3 | 1989 | 1023 | 0.030 |
Why?
|
Parkinson Disease | 4 | 1988 | 2775 | 0.030 |
Why?
|
Patient Education as Topic | 2 | 2012 | 2278 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2012 | 68 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 1624 | 0.030 |
Why?
|
Regional Blood Flow | 1 | 2015 | 1525 | 0.030 |
Why?
|
Deferoxamine | 1 | 2012 | 151 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2013 | 517 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2014 | 502 | 0.020 |
Why?
|
Models, Economic | 1 | 2016 | 713 | 0.020 |
Why?
|
Heart Function Tests | 1 | 2012 | 330 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2018 | 2715 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2003 | 3617 | 0.020 |
Why?
|
Myocardial Stunning | 1 | 2011 | 68 | 0.020 |
Why?
|
Cell Size | 1 | 2013 | 643 | 0.020 |
Why?
|
Vena Cava, Inferior | 1 | 2014 | 440 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2020 | 2416 | 0.020 |
Why?
|
Cost Savings | 1 | 2016 | 926 | 0.020 |
Why?
|
Troponin I | 1 | 2014 | 619 | 0.020 |
Why?
|
International Cooperation | 1 | 2017 | 1420 | 0.020 |
Why?
|
Infant, Newborn | 3 | 2015 | 25625 | 0.020 |
Why?
|
Cardiac Myosins | 1 | 2010 | 117 | 0.020 |
Why?
|
Health Planning Guidelines | 1 | 2010 | 163 | 0.020 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2012 | 472 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2014 | 1475 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15295 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2003 | 11366 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1769 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2017 | 1504 | 0.020 |
Why?
|
Dipyridamole | 1 | 2009 | 145 | 0.020 |
Why?
|
Comprehension | 1 | 2014 | 610 | 0.020 |
Why?
|
Smoking | 1 | 2006 | 8987 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1850 | 0.020 |
Why?
|
Carrier Proteins | 2 | 2014 | 5021 | 0.020 |
Why?
|
Random Allocation | 1 | 2013 | 2429 | 0.020 |
Why?
|
Myosin Heavy Chains | 1 | 2010 | 414 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2018 | 2494 | 0.020 |
Why?
|
Dosage Forms | 1 | 1988 | 56 | 0.020 |
Why?
|
Cytokines | 1 | 2023 | 7322 | 0.020 |
Why?
|
3-Iodobenzylguanidine | 1 | 2009 | 115 | 0.020 |
Why?
|
Wisconsin | 1 | 1988 | 124 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 362 | 0.020 |
Why?
|
Biofeedback, Psychology | 1 | 1989 | 115 | 0.020 |
Why?
|
Stereotaxic Techniques | 2 | 1987 | 536 | 0.020 |
Why?
|
Dogs | 1 | 2012 | 3912 | 0.020 |
Why?
|
Collagen Type I | 1 | 2010 | 592 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2274 | 0.020 |
Why?
|
Models, Statistical | 2 | 2015 | 5102 | 0.020 |
Why?
|
Ticlopidine | 1 | 2012 | 899 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2016 | 21827 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2886 | 0.020 |
Why?
|
Whole Body Imaging | 1 | 2009 | 280 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2012 | 1240 | 0.020 |
Why?
|
Injections | 1 | 2010 | 840 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2019 | 3297 | 0.020 |
Why?
|
Intraoperative Care | 1 | 2010 | 767 | 0.020 |
Why?
|
Physical Examination | 1 | 2012 | 1237 | 0.020 |
Why?
|
Renal Circulation | 1 | 2007 | 333 | 0.020 |
Why?
|
Electromyography | 3 | 1988 | 1379 | 0.020 |
Why?
|
Polysomnography | 1 | 2012 | 1776 | 0.020 |
Why?
|
Vascular Resistance | 1 | 2009 | 936 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2011 | 921 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3703 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2012 | 956 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 1125 | 0.020 |
Why?
|
Reference Values | 1 | 2013 | 4982 | 0.020 |
Why?
|
Systems Integration | 1 | 2007 | 440 | 0.020 |
Why?
|
Stents | 1 | 2017 | 3280 | 0.020 |
Why?
|
Liver | 2 | 2012 | 7474 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4456 | 0.020 |
Why?
|
Brachial Artery | 1 | 2007 | 369 | 0.020 |
Why?
|
Triglycerides | 1 | 2013 | 2454 | 0.020 |
Why?
|
Device Removal | 1 | 2010 | 656 | 0.020 |
Why?
|
Prosthesis Implantation | 1 | 2010 | 642 | 0.020 |
Why?
|
Child | 4 | 2015 | 77709 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2010 | 2124 | 0.020 |
Why?
|
Subtraction Technique | 1 | 2007 | 525 | 0.020 |
Why?
|
Internet | 1 | 2017 | 3064 | 0.020 |
Why?
|
Tricuspid Valve | 1 | 2007 | 403 | 0.010 |
Why?
|
Autoantibodies | 1 | 2012 | 2035 | 0.010 |
Why?
|
Prosthesis Design | 1 | 2010 | 2110 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3597 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5319 | 0.010 |
Why?
|
Lipids | 1 | 2014 | 3305 | 0.010 |
Why?
|
Cause of Death | 1 | 2014 | 3584 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2002 | 5221 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2012 | 2356 | 0.010 |
Why?
|
Albuminuria | 1 | 2007 | 682 | 0.010 |
Why?
|
Feedback | 1 | 1987 | 795 | 0.010 |
Why?
|
Cost of Illness | 1 | 2012 | 1859 | 0.010 |
Why?
|
Potassium | 1 | 2007 | 1336 | 0.010 |
Why?
|
Infant | 2 | 2015 | 35136 | 0.010 |
Why?
|
Plaque, Atherosclerotic | 1 | 2014 | 1519 | 0.010 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 2291 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8428 | 0.010 |
Why?
|
Medicare | 1 | 2020 | 6566 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2007 | 2029 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3778 | 0.010 |
Why?
|
Central Nervous System | 1 | 1989 | 1357 | 0.010 |
Why?
|
Cloning, Molecular | 2 | 1998 | 4320 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2007 | 2971 | 0.010 |
Why?
|
Oxygen | 1 | 2012 | 4189 | 0.010 |
Why?
|
Life Style | 1 | 2012 | 3835 | 0.010 |
Why?
|
Health Status | 1 | 2014 | 4034 | 0.010 |
Why?
|
Health Behavior | 1 | 2012 | 2636 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2012 | 2071 | 0.010 |
Why?
|
Action Potentials | 1 | 1988 | 1806 | 0.010 |
Why?
|
Models, Neurological | 1 | 1989 | 1774 | 0.010 |
Why?
|
Administration, Oral | 1 | 1988 | 3913 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2012 | 3068 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2012 | 3966 | 0.010 |
Why?
|
Macrophages | 1 | 2014 | 5655 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 2957 | 0.010 |
Why?
|
Clinical Competence | 1 | 2015 | 4687 | 0.010 |
Why?
|
Bleomycin | 1 | 1980 | 512 | 0.010 |
Why?
|
Plants, Genetically Modified | 1 | 1998 | 110 | 0.010 |
Why?
|
Vinblastine | 1 | 1980 | 502 | 0.010 |
Why?
|
Peptides | 1 | 2010 | 4409 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 2716 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1998 | 878 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 12072 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2002 | 13102 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 9959 | 0.010 |
Why?
|
Heart Valve Diseases | 1 | 2003 | 1073 | 0.010 |
Why?
|
Radiotherapy | 1 | 2002 | 1533 | 0.010 |
Why?
|
Computer Simulation | 1 | 2008 | 6196 | 0.010 |
Why?
|
Cisplatin | 1 | 1980 | 1662 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 1980 | 804 | 0.010 |
Why?
|
Depression | 1 | 2012 | 7766 | 0.010 |
Why?
|
Mutagenesis | 1 | 1995 | 1266 | 0.010 |
Why?
|
DNA Primers | 1 | 1995 | 2892 | 0.010 |
Why?
|
Neurons | 2 | 1987 | 9338 | 0.010 |
Why?
|
Stochastic Processes | 1 | 1989 | 344 | 0.000 |
Why?
|
Antibodies | 1 | 1995 | 2460 | 0.000 |
Why?
|
Binding Sites | 1 | 1995 | 6114 | 0.000 |
Why?
|
Base Sequence | 1 | 1995 | 12797 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1998 | 13033 | 0.000 |
Why?
|
Cell Line | 1 | 1995 | 15997 | 0.000 |
Why?
|
Muscles | 1 | 1985 | 1614 | 0.000 |
Why?
|
Leukopenia | 1 | 1980 | 212 | 0.000 |
Why?
|
Evoked Potentials | 1 | 1985 | 1056 | 0.000 |
Why?
|
Synaptic Transmission | 1 | 1985 | 1178 | 0.000 |
Why?
|
Thrombocytopenia | 1 | 1980 | 1179 | 0.000 |
Why?
|
Gastrointestinal Diseases | 1 | 1980 | 1170 | 0.000 |
Why?
|
Neoplasm Metastasis | 1 | 1980 | 4851 | 0.000 |
Why?
|
Neoplasm Staging | 1 | 1980 | 11031 | 0.000 |
Why?
|